# A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease

Study · id `cardio:ct-nct01843790` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01843790](<https://clinicaltrials.gov/study/NCT01843790>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01843790

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

## Technical summary

Registry record NCT01843790. Randomized; single masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2014-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (enrolled count; ClinicalTrials.gov record NCT01843790, source copy `cardio:ctgov-nct01843790-2015-09-01`, retrieved 2026-10-26)
- Start date: 2013-06 (registry gives no type) (ClinicalTrials.gov record NCT01843790, source copy `cardio:ctgov-nct01843790-2015-09-01`, retrieved 2026-10-26)
- Primary completion: 2014-02 (actual) (ClinicalTrials.gov record NCT01843790, source copy `cardio:ctgov-nct01843790-2015-09-01`, retrieved 2026-10-26)
- Completion: 2014-09 (actual) (ClinicalTrials.gov record NCT01843790, source copy `cardio:ctgov-nct01843790-2015-09-01`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01843790, source copy `cardio:ctgov-nct01843790-2015-09-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01843790-2015-09-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease
- Condition: Chronic Kidney Disease
- Intervention (Drug): GCS-100
- Intervention (Drug): Placebo, Saline
- Lead sponsor: La Jolla Pharmaceutical Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: 836780159c7bb9c2f3cc3b655e994ac090a12658dc702ee4b9e9c25af87cdf61
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
